Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 11/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.43 |
| ▸ | TNF | P01375 | 3/20 | 0.40 |
| ▸ | MYLK | Q15746 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943982 | 0.88 | MAP3K5 (0.53) | MAP3K5TNFMYLK | |
| SCHEMBL30558025 | 0.88 | MAP3K5 (0.53) | MAP3K5TNFMYLK | |
| SCHEMBL20802774 | 0.85 | MAP3K5 (0.48) | MAP3K5MAP4K1TNFMYLK | |
| SCHEMBL20802751 | 0.85 | MAP3K5 (0.48) | MAP3K5MAP4K1TNFMYLK | |
| SCHEMBL22404532 | 0.84 | MAP3K5 (0.47) | MAP3K5MAP4K1TNFMYLK | |
| SCHEMBL21724515 | 0.82 | MAP3K5 (0.50) | MAP3K5MAP4K1TNFMYLK | |
| SCHEMBL22474083 | 0.82 | MAP3K5 (0.53) | MAP3K5TNFMYLK | |
| SCHEMBL20803414 | 0.82 | TNF (0.48) | MAP3K5TNFMYLK | |
| SCHEMBL22404523 | 0.78 | MAP3K5 (0.42) | MAP3K5TNFMYLK | |
| SCHEMBL20803424 | 0.78 | MAP3K5 (0.44) | MAP3K5TNFMYLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | Fuijan Cosunter Pharmaceutical Co. Ltd. (CN) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | MARK1, MAP3K1, MAP3K20 | MAP3K5 10/4885MAP4K1 27/4885TNF 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.